Assessment of Clinical Risk Factors and Survival Outcomes in Postoperative Recurrence or Metastasis of Colorectal Cancer - Report - MDSpire

Assessment of Clinical Risk Factors and Survival Outcomes in Postoperative Recurrence or Metastasis of Colorectal Cancer

  • By

  • Haoran Zhu

  • Yuankun Cai

  • ChongWei Ke

  • Huipeng Wang

  • February 24, 2026

  • 0 min

Share

Clinical Report: Assessment of Clinical Risk Factors and Survival Outcomes in Postoperative Recurrence or Metastasis of Colorectal Cancer

Overview

This study evaluates clinical risk factors associated with postoperative recurrence and metastasis in colorectal cancer patients. It highlights the significant impact of these factors on survival outcomes, emphasizing the need for effective risk assessment in clinical practice.

Background

Colorectal cancer is a leading cause of cancer-related mortality worldwide, with a notable recurrence rate following surgical intervention. Identifying risk factors for recurrence is crucial for improving patient management and survival rates. Understanding these factors can guide treatment decisions and enhance postoperative monitoring strategies.

Data Highlights

Patient GroupNumber of Patients
Rectal Cancer185
Colon Cancer234

Key Findings

  • The local recurrence rate of colorectal cancer after radical surgery ranges from 4% to 30%.
  • The 5-year survival rate for patients with locally recurrent colorectal cancer is between 22% and 58%.
  • Once recurrence or metastasis occurs, the 5-year survival rate drops to less than 5%.
  • Pelvic enhanced MRI is effective in assessing mesocolic fascia infiltration before surgery.
  • Inter-observer reliability for MRI assessments showed a Kappa coefficient of 0.82, indicating good consistency.

Clinical Implications

Clinicians should prioritize the identification of risk factors for recurrence in colorectal cancer patients to optimize postoperative care. Enhanced imaging techniques like MRI can aid in preoperative assessments, potentially improving surgical outcomes and survival rates.

Conclusion

The study underscores the importance of recognizing clinical risk factors in colorectal cancer to mitigate recurrence and improve survival outcomes. Ongoing research is essential to refine risk assessment strategies in this patient population.

References

  1. Prognostic Evaluation of Recurrent Colorectal Cancer Using Hazard Function Analysis, 2024
  2. Identifying Early Recurrence in Patients After Resection of Primary Colorectal Cancer and Associated Risk Factors, 2021
  3. Impact of Initial Treatment Strategies on Prognosis Following Recurrence in Locally Advanced Rectal Cancer: Findings from a Retrospective Cohort Study, 2024
  4. Identifying Risk Factors for Metachronous Adenoma in the Remaining Colon of Colorectal Cancer Patients Post-Surgery, 2017
  5. Adjuvant Chemotherapy for Stage II Colon Cancer - PMC
  6. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
  7. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial - PMC
  8. Adjuvant Chemotherapy for Stage II Colon Cancer - PMC
  9. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials - ScienceDirect
  10. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial - PMC

Original Source(s)

Related Content